2024
The nature of chronic rejection after lung transplantation: a murine orthotopic lung transplant study
Heigl T, Kaes J, Aelbrecht C, Serré J, Yamada Y, Geudens V, Van Herck A, Vanstapel A, Sacreas A, Ordies S, Frick A, Gimenez B, Van Slambrouck J, Beeckmans H, Oztürk N, Orlitova M, Vaneylen A, Claes S, Schols D, Velde G, Schupp J, Kaminski N, Boesch M, Korf H, van der Merwe S, Dupont L, Vanoirbeek J, Godinas L, Van Raemdonck D, Janssens W, Gayan-Ramirez G, Ceulemans L, McDonough J, Verbeken E, Vos R, Vanaudenaerde B. The nature of chronic rejection after lung transplantation: a murine orthotopic lung transplant study. Frontiers In Immunology 2024, 15: 1369536. PMID: 38736881, PMCID: PMC11084670, DOI: 10.3389/fimmu.2024.1369536.Peer-Reviewed Original ResearchConceptsChronic lung allograft dysfunctionChronic rejectionLung transplantationSingle cell RNASingle cell RNA profilingOrthotopic left lung transplantationComplications post-transplantationLung allograft dysfunctionMouse lung transplantationLeft lung transplantationLung transplantation studiesAllograft dysfunctionPleural infiltrationPost-transplantationBronchiolitis obliteransInnate inflammationChronic complicationsPrimary onsetEndothelial destructionTransplantationDay 7Immunological perspectiveArterial responseTransplantation studiesLung
2023
Calcineurin-inhibitor free immunosuppression after lung transplantation – a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors
Gottlieb J, Fischer B, Schupp J, Golpon H. Calcineurin-inhibitor free immunosuppression after lung transplantation – a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors. PLOS ONE 2023, 18: e0284653. PMID: 37200246, PMCID: PMC10194991, DOI: 10.1371/journal.pone.0284653.Peer-Reviewed Original ResearchConceptsCNI-free immunosuppressionCalcineurin inhibitor-free immunosuppressionMTOR inhibitorsFree immunosuppressionLung transplantationImproved survivalRapamycin inhibitorsNeurological diseasesSingle-center case-control studyCenter case-control studyCNI-free regimenCurative treatment optionGlomerular filtration rateMajority of patientsNon-malignant indicationsSignificant functional improvementCase-control studyMechanistic targetAcute rejectionLTx patientsNeurological complicationsAdult patientsMedian durationSingle centerTreatment options
2022
Feasibility of Prolonged Calcineurin-Inhibitor Free Immunosuppression After Lung Transplantation - A Retrospective Single Center Analysis
Gottlieb J, Valtin C, Fischer B, Schupp J, Golpon H. Feasibility of Prolonged Calcineurin-Inhibitor Free Immunosuppression After Lung Transplantation - A Retrospective Single Center Analysis. The Journal Of Heart And Lung Transplantation 2022, 41: s421. DOI: 10.1016/j.healun.2022.01.1061.Peer-Reviewed Original ResearchProliferation signal inhibitorsCalcineurin inhibitor-free immunosuppressionChronic lung allograft dysfunctionRetrospective single-center analysisSingle-center analysisFree immunosuppressionCurative intentionMedian glomerular filtration rateCenter analysisCNI-free immunosuppressionLung allograft dysfunctionTriple-drug regimenGlomerular filtration rateNon-malignant indicationsAllograft dysfunctionEvaluable patientsIS regimenLung transplantationTriple regimenNeurological complicationsPalliative settingDrug regimenInduction agentCase reportFiltration rate
2020
Cathepsin B promotes collagen biosynthesis, which drives bronchiolitis obliterans syndrome
Morrone C, Smirnova NF, Jeridi A, Kneidinger N, Hollauer C, Schupp JC, Kaminski N, Jenne D, Eickelberg O, Yildirim AÖ. Cathepsin B promotes collagen biosynthesis, which drives bronchiolitis obliterans syndrome. European Respiratory Journal 2020, 57: 2001416. PMID: 33303550, DOI: 10.1183/13993003.01416-2020.Peer-Reviewed Original ResearchConceptsBronchoalveolar lavage fluidCathepsin B activityHealthy donorsLung tissueCollagen depositionB activityCathepsin BBronchiolitis obliterans syndromeProgression of BOSFluorescence resonance energy transfer-based assayPromising therapeutic targetGrowth factor-β1Cathepsin B levelsSubsequent collagen depositionBOS pathogenesisBOS patientsBOS progressionLTx patientsLymphocytic bronchiolitisObliterans syndromeLung transplantationPeribronchial fibrosisPulmonary dysfunctionLung functionMajor complications
2015
Diagnostik und Therapie der Sarkoidose
Frye B, Schupp J, Köhler T, Müller-Quernheim J. Diagnostik und Therapie der Sarkoidose. Der Internist 2015, 56: 1346-1352. PMID: 26563335, DOI: 10.1007/s00108-015-3757-1.ChaptersConceptsIntrathoracic lymph nodesLymph nodesGranulomatous diseaseSteroid-refractory diseaseFurther therapeutic optionsNon-necrotizing granulomasDiagnostik und TherapieLung transplantationSarcoidosis treatmentSteroid therapyCNS involvementStarting doseSymptomatic therapyOrgan impairmentTherapeutic optionsUnd TherapieEndobronchial ultrasoundSpontaneous resolutionBody weightSarcoidosisOrphan diseaseMonoclonal antibodiesDiseaseSymptomatic patternGranulomas